Extensive pre-clinical data demonstrated the immunotherapy’s ability to overcome tumor self-tolerance and provide anti-tumor immunostimulatory effect including strong activated, functional intra-tumoral CD8+ T cell infiltration. This evidence concerns the gene CD8A and neoplasm.